Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

Published

Journal Article

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma. These include the addition of regimens containing novel agents as primary and salvage therapy options, inclusion of the updated summary of response categories and criteria from the sixth international workshop on Waldenström's Macroglobulinemia, and a section on management of peripheral neuropathy in the accompanying discussion.

Full Text

Duke Authors

Cited Authors

  • Anderson, KC; Alsina, M; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Ilizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Medeiros, BC; Meredith, R; Raje, N; Schriber, J; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Tricot, G; Weber, DM; Yahalom, J; Yunus, F; Kumar, R; Shead, DA; NCCN (National Comprehensive Cancer Network),

Published Date

  • October 1, 2012

Published In

Volume / Issue

  • 10 / 10

Start / End Page

  • 1211 - 1219

PubMed ID

  • 23054875

Pubmed Central ID

  • 23054875

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Language

  • eng

Conference Location

  • United States